Production (Stage)
Channel Therapeutics Corporation
CHRO
$1.22
-$0.0065-0.53%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 194.30K | -894.20K | 414.60K | 13.00K | 466.60K |
| Gross Profit | -194.30K | 894.20K | -414.60K | -13.00K | -466.60K |
| SG&A Expenses | 1.64M | 1.54M | 1.63M | 1.75M | 1.47M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.83M | 1.83M | 2.05M | 1.76M | 1.93M |
| Operating Income | -1.83M | -1.83M | -2.05M | -1.76M | -1.93M |
| Income Before Tax | -1.97M | -1.93M | -1.69M | -1.77M | -2.56M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.97M | -1.93M | -1.69M | -1.77M | -2.56M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.97M | -1.93M | -1.69M | -1.77M | -2.56M |
| EBIT | -1.83M | -1.83M | -2.05M | -1.76M | -1.93M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.32 | -0.32 | -0.29 | -0.31 | -0.55 |
| Normalized Basic EPS | -0.20 | -0.20 | -0.22 | -0.19 | -0.34 |
| EPS Diluted | -0.32 | -0.32 | -0.29 | -0.31 | -0.55 |
| Normalized Diluted EPS | -0.20 | -0.20 | -0.22 | -0.19 | -0.34 |
| Average Basic Shares Outstanding | 6.13M | 6.04M | 5.79M | 5.77M | 4.69M |
| Average Diluted Shares Outstanding | 6.13M | 6.04M | 5.79M | 5.77M | 4.69M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |